Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips(AbbVie (United States)), Edward B. Reilly(AbbVie (United States)), Lise I. Loberg(AbbVie (United States)), Chung-Ming Hsieh(Abbott (United States)), David R. Reuter(AbbVie (United States)), Hui Gan(Austin Hospital), Sanjay C. Panchal(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Kedar S. Vaidya(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Peter J. DeVries(AbbVie (United States)), Kenneth R. Durbin(AbbVie (United States)), Sherry L. Ralston(AbbVie (United States)), Jonathan A. Meulbroek(Abbott Fund), Sarah R. Mudd(AbbVie (United States)), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Diana Cao(Austin Hospital), Hugh D. Falls(AbbVie (United States)), Martin J. Voorbach(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Lorenzo Benatuil(Abbott (United States))
Cited by 52
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|853
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.
|Proceedings of the National Academy of Sciences|1994|806